Focused Issue on Mechanisms of Resistance to EGFR-targeted Therapy

Posted On 2019-06-21 08:07:47



This focused issue on “Mechanisms of Resistance to EGFR-targeted Therapy” is edited by Dr. Trever Bivona, Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA, USA.

Dr. Bivona is a cell and molecular biologist and a board-certified medical oncologist. He received his MD and PhD degrees from NYU School of Medicine, followed by internal medicine training at the Brigham and Women’s Hospital/Harvard Medical School in Boston, and medical oncology and post-doctoral research training at the Memorial Sloan-Kettering Cancer Center in New York. Dr. Bivona then joined the faculty at the University of California, San Francisco where he is currently an Associate Professor and directs a basic and translational research program investigating oncogene signaling pathways and the molecular basis of response and resistance to cancer therapeutics.

Focused issue outline:

  1. Introduction to this focused issue
    Trever Bivona, University of California, San Francisco, CA, USA
  2. Mechanisms of resistance to osimertinib
    Rafael Rosell, Germans Trias i Pujol Health Sciences Institute and Hospital Badalona, Barcelona, Spain
  3. Acquired resistance
    Jonathan Riess, UC Davis Comprehensive Cancer Center, Sacramento, USA
  4. Liquid biopsy
    Hatim Hussain, UC San Diego Health - La Jolla, Moores Cancer Center, San Diego, USA
  5. Co-mutations
    Collin Blakely, University of California, San Francisco, USA
  6. Tumor evolution
    Caroline McCoach, University of California, San Francisco, USA
  7. Tumor microenvironment biology and therapeutic opportunities
    Julia Rotow, University of California, San Francisco, USA